Dumping drug discovery makes Tysabri-rich Elan tastier takeover target
This article was originally published in Scrip
Elan could look like an attractive takeover target for a big pharma or biotech company looking for an uncomplicated profit boost, now that it has announced plans to split out its profitable Tysabri and later-stage assets from its early-stage drug discovery business and cut its workforce down from 380 to around 170-190 across the two firms. The front-runner for potential bids would indeed probably be its Tysabri partner Biogen Idec.
You may also be interested in...
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Sanofi pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.